Answers are grounded in this paper and cite their sources.
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Bimekizumab (Bimzelx), 160 mg/mL solution for subcutaneous injection. Indication: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
No takes yet. Share an insight, caveat, or question.
CADTH (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: